Biogen completes enrollment for relapsing multiple sclerosis study
29th August 2008
By Staff Writer
Biogen Idec has completed enrollment in the Assurance trial, a long-term follow-up study which will assess up to 15 years of Avonex treatment in an effort to provide detailed data on the long-term efficacy of the drug.
Assurance is a multi-center, open-label follow-up study of patients with relapsing multiple sclerosis (MS) treated with Avonex or placebo for at least two years in the Phase III pivotal trial.
Leaving comments is a great way to get others involved with the topic. Please feel free to leave your comment(s) for any of the postings found on this blog.